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Abstract
Secondary metabolites are well known for their ability to impede other microorganisms. Reanalysis of a screen of natural
products using the Caenorhabditis elegans-Candida albicans infection model identified twelve microbial secondary
metabolites capable of conferring an increase in survival to infected nematodes. In this screen, the two compound
treatments conferring the highest survival rates were members of the epipolythiodioxopiperazine (ETP) family of fungal
secondary metabolites, acetylgliotoxin and a derivative of hyalodendrin. The abundance of fungal secondary metabolites
indentified in this screen prompted further studies investigating the interaction between opportunistic pathogenic fungi
and Aspergillus fumigatus, because of the ability of the fungus to produce a plethora of secondary metabolites, including the
well studied ETP gliotoxin. We found that cell-free supernatant of A. fumigatus was able to inhibit the growth of Candida
albicans through the production of a secreted product. Comparative studies between a wild-type and an A. fumigatus DgliP
strain unable to synthesize gliotoxin demonstrate that this secondary metabolite is the major factor responsible for the
inhibition. Although toxic to organisms, gliotoxin conferred an increase in survival to C. albicans-infected C. elegans in a dose
dependent manner. As A. fumigatus produces gliotoxin in vivo, we propose that in addition to being a virulence factor,
gliotoxin may also provide an advantage to A. fumigatus when infecting a host that harbors other opportunistic fungi.
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Introduction
Microbial secondary metabolites have provided numerous
pharmaceutical agents ranging from antibiotics to immunosuppres-
sive compounds. Synthesis of these low molecular weight com-
pounds is not required for normal growth of the microbe, however
these compounds may provide several benefits to the organism.
Fungi have the ability to produce a plethora of secondary me-
tabolites, typically dependent on the stage of development of the
fungus and environmental factors ranging from nutrient concen-
trations to light andtemperature [1,2].Fungibelongingto the genus
Aspergillus areespeciallycapable ofproducinga diversearrayofthese
compounds [3,4]. The filamentous fungus Aspergillus fumigatus
secretes more than 226 secondary metabolites including commonly
studied polyketides, such as cyclic peptides, alkaloids, and
sesquiterpenoids [4]. Members of another class of secondary
metabolites produced by A. fumigatus, termed the epipolythiodiox-
opiperazines (ETPs), are characterized by an internal disulphide
bridge across a diketopiperazine ring, where the first and best
characterized member being gliotoxin [5].
A. fumigatus spores are ubiquitous in the environment and are
commonly inhaled. Invasive aspergillosis usually only effects
immune-compromised patients (those with leukemia, transplanta-
tion) or patients with other medical conditions such as cystic
fibrosis, chronic obstructive pulmonary disease, or severe asthma,
as the primary route to an established infection is through the
lungs [6]. Among different Aspergillus species, only those associated
with aspergillosis, such as A. fumigatus, A. terreus, A. flavus, and A.
niger, produce gliotoxin [7,8]. Conversely, A. nidulans, a saprobe not
normally associated with invasive aspergillosis, does not have the
secondary metabolite gene cluster necessary to produce gliotoxin
or any other ETP [9]. The role of gliotoxin in mammalian
virulence is not fully known as conflicting results exist (recently
reviewed in [10]). In A. fumigatus, the gliotoxin secondary
metabolite gene cluster is composed of 12 genes approximately
28 kb in length (the gli cluster) [11]. Dioxopiperazine synthase
(GliP) is required in the first step for the biosynthesis of gliotoxin
generating the characteristic diketopiperizine ring [5,12].
Factors which enable A. fumigatus to colonize and remain
established within the host by competing for limited available
nutritional resources are currently unknown; however gliotoxin
has potent antifungal activity against Candida albicans, Cryptococcus
neoformans, and other fungi [13]. This is interesting because
pathogenic fungi, such as C. albicans and C. neoformans, primarily
infect or colonize hospitalized patients and particularly the same
patient population as A. fumigatus, providing an environment
conducive of pathogen-pathogen interactions between these fungi,
in particular within the pulmonary system. For example,
concurrent co-infection/colonization of Aspergillus spp. and Candida
spp. can occur in patients [14]. Moreover, Candida spp. can
colonize the respiratory tract of hospitalized patients, and the
ability of a fungus such as A. fumigatus to compete against a
previously established Candida spp. colonization may be necessary
for the second pathogen to develop an infection.
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Candida-infected nematode survival assay to identify secondary
metabolites capable of prolonging nematode survival. We found
that two members of the ETP class of secondary metabolites we
able to significantly increase nematode survival after infection with
C. albicans. As pathogenic fungi are capable of producing these
compounds within a host, the inhibitory action of gliotoxin against
C. albicans was further studied. This research investigates the
potential antagonistic activities mediated by secondary metabolites
that may be occurring among fungi within a host.
Results and Discussion
Secondary metabolites promoting Candida-infected
Caenorhabditis elegans survival
The C. albicans-C. elegans antifungal discovery assay allows
simultaneous assessment of the ability of a compound to promote
survival of infected nematodes and indicate if there is any
associated potential toxicity [15]. Previously, a high-throughput
screen of 2,560 natural products from the Analyiticon Discovery
compound collection (www.ac-discovery.com) was conducted that
identified several plant produced saponins that confer an increase
in Candida-infected nematode survival [16]. In addition to these
saponins, reanalysis of this screen also identified twelve microbial
secondary metabolites that were able to prolong nematode survival
and may have antifungal activity (Figure 1; Table 1). These
compounds were produced by bacteria and fungi, and several
natural products that were closely related to known antifungal
compounds were identified in this screen. Compounds conferring
C. albicans-infected nematode survival rates greater then 40% were
chosen for further discussion.
Interestingly, two members (A3 and A22) of the ETP family of
secondary metabolites provided the highest worm survival of the
natural products screened (Figure 1; Table 1) and A22 (80%) and
A3 (73%) promoted greater than 65% nematode survival
(Figure 1). Of note is that the dose response for nematode survival
for both of these ETP compounds was comparable to amphoter-
icin B (Figure 2). Toxicity for acetylgliotoxin was observed in the
C. elegans assay at higher concentrations (.16 mg/ml; Figure 2), no
toxicity was seen at the highest concentration tested for A22
(31 mg/ml; Figure 2). A number of ETP secondary metabolites are
synthesized by fungi [5]. The most common form of this class of
compounds contains a disulphide bridge, but sometimes versions
containing one, three, or four sulfur atoms are also produced [5].
The disulphide bridge containing form of A22 has been previously
isolated from Hyalodendron sp. and identified as hyalodendrin [17],
one of the few ETP compounds produced by a basidiomycete [5].
Among the other secondary metabolites, compound A15
(tunicamycin V) is a member of the tunicamycin family of
antimicrobial agents with a modified fatty acid side-chain (Figure 1)
[18]. Tunicamycin is a mixture of homologous nucleoside
compounds and inhibits N-linked glycosylation [19]. Tunicamycin
is highly toxic if swallowed, and targets the liver and nerves.
However, the (E)-13-methyltetradec-2-enoic acid substituted
analog tunicamycin V gave up to 60% protection to the worms
and showed no signs of toxicity in the screen. Several tunicamycin
homologues have previously been reported to inhibit C. albicans,
and their degree of toxicity varied depending on the fatty-acid side
chain [20].
Importantly, distinct structure activity relationships were
discernible between several closely related analogs in the
antifungal screen. For example, two members of the enniatin
family of natural products, enniatin A (A5) and enniatin B1 (A12),
produced by Fusarium spp. were active in the assay [21]. This class
is characterized by the alternating arrangement of ester and amide
linkages comprising an 18 membered macrocycle. Enniatin A and
enniatin B1 differ by only two methyl substitutions and
demonstrated protective activity with the isovaleroyl substituted
enniatin A being twice as effective, 47% vs 20% respectively
(Figure 1). The protective activity of the enniatins is reflected in
their MIC, as enniatin A inhibits C. albicans growth at half the
concentration as enniatin B1 [22]. These compounds did not
display toxicity to the worms in subsequent dose-response
experiments, however the enniatins provided a low degree of
protection to the worms.
Another notable secondary metabolite, desferrioxamine X
belongs to the well-studied class of hydroxamate siderophores
[23,24]. This class of cyclic hexadentate siderpohores are specific
chelators of iron(III) and are produced by a variety of bacteria and
fungi under iron deficient conditions. These hydroxamate based
macrocycles sequester and solubilize iron(III) which is then
actively transported into the organism. While siderophores have
been utilized in humans for iron and aluminum overload therapy
and some antibiotic applications, use of desferrioxamine in C.
albicans treatment has not been extensively studied. However,
desferrioxamine increases severity of mycoses caused by some
fungi, in particular pathogenic members of the order Mucorales,
as the fungi are able to uptake and utilize the iron chelated by the
siderophore, although there appears to be no significant difference
with C. albicans [25,26]. While the overall protective effect was
moderate, 40%, desferrioxamine X showed no toxicity to the
worms at higher concentrations.
Finally, the secondary metabolite ascochlorin (A1), also referred
to as ilicicolin D, is an prenyl-phenol compound that was originally
identified in extracts of the fungus Ascochyta viciae [27]. Ascochlorin
inhibits mitochondrial electron transport via binding to the Qi and
Qo sites of the cytochrome bc1 complex [28]. Interestingly, another
secondary metabolite identified in the screen, ilicicolin H (A4)
produced by the fungus Cylindrocladium iliciola, also acts by
inhibiting the cytochrome bc1 complex, however this molecule
binds at the Qn site [29]. Both ascochlorin and ilicicolin H
conferred a similar C. albicans-infected nematode survival rate
(40% and 33%, respectively; Figure 1 and Table 1).
Secondary metabolites from A. fumigatus inhibit other
opportunistic fungi
The secondary metabolites produced by A. fumigatus were
chosen for additional investigation. This fungus was chosen for
further studies with C. albicans and C. neoformans because of the
numerous secondary metabolites known to be synthesized and
have been characterized, including gliotoxin, the deacetylated
version of A3. Although rare, concurrent fungal infection/
colonization between A. fumigatus and C. albicans or C. neoformans
have been documented [14]. Isolation of Candida spp. from
respiratory specimens is generally not indicative of colonization,
but rather is the result of contamination of the bronchoscope from
the gastrointestinal tract during the examination procedure.
However, it is notable that in a study of postmortem examinations,
six (4.8%) revealed concurrent Aspergillus spp. and Candida spp.
infection and one with Aspergillus spp. and C. neoformans (,1%)
[14].
When A. fumigatus was co-inoculated with C. albicans or C.
neoformans on plates containing Spider medium at 37uC, yeast
colonies proximal to A. fumigatus were unable to grow (data not
shown), suggesting that A. fumigatus produces a secreted toxic agent
to both C. albicans and C. neoformans at the stationary phase. In
order to identify if any secondary metabolites of A. fumigatus were
responsible for the growth inhibition to C. albicans and C.
Secondary Metabolites with Antifungal Activity
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2 mg of AFS was able to form a zone of inhibition around C.
albicans strains DAY185, 95–120, or 98–145 on plates containing
Spider medium and grown at 37uC (Figure 3); a zone of inhibition
was also observed with C. neoformans KN99a on YPD plates grown
at 30uC (Figure 3). AFS was also able to produce a slight zone of
inhibition around the C. albicans strains at 30uC on YPD plates
(data not shown).
To further assess the nature of the secreted product(s) in the
supernatant that are responsible for the inhibition of C. albicans and
C. neoformans, the supernatant was heated at 60uC for 2 hours to
inactivate potential enzymatic activity. The inhibitory activity of the
Figure 1. Compound structures of secondary metabolites able to confer an increase in survival to Candida-infected nematodes. The
maximum nematode survival (%) and molecular weights are indicated for each of the compounds. Structures were provided by Analyticon Discovery.
doi:10.1371/journal.pone.0025321.g001
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DAY185 and was able to produce a zone of inhibition on plates
containing Spider medium and grown at 37uC (Figure S1), similar to
the results observed with AFS. As a negative control the fungal
inhibitory potential of the C. neoformans supernatant was assessed on C.
albicans growth. The C. neoformans supernatant was unable to produce
a zone of inhibition with C. albicans DAY185 when grown on either
YPD at 30uCo rS p i d e rm e d i u ma t3 7 uC (Figure S2). Taken together,
these data suggest that AFS contains heat stable product(s), possibly
secondary metabolites, which were secreted from the fungus capable
of inhibiting the growth of C. albicans and C. neoformans.
Gliotoxin is the major secondary metabolite of A.
fumigatus that is toxic to C. albicans and C. neoformans
The A. fumigatus DgliP3 mutant strain that does not produce
gliotoxin [12] was used to investigate if gliotoxin produced by A.
fumigatus is responsible for the inhibitory activity of the supernatant to
C. albicans and C. neoformans. Unlike the supernatant from the wild type
AF293 strain, the supernatant of the DgliP isolate failed to produce a
zone of inhibition for either C. albicans strains DAY185, 95–120, 98–
145, or C. neoformans KN99a, demonstrating that gliotoxin was
responsible for the zone of inhibition observed with all the C. albicans
and C. neoformans strains. Further studies on the inhibitory activity of
Figure 2. Dose response of two ETP compounds from the C. albicans-C. elegans antifungal discovery assay. A22 and A3 were as effective
as amphotericin B in increasing nematode survival, however the decrease observed for compound A3 suggests there maybe toxicity associated with
the compound at higher concentrations. The dose response experiment was conducted a single time as previously reported in Okoli et al., 2009.
doi:10.1371/journal.pone.0025321.g002
Table 1. Compounds identified in a screen of natural products containing secondary metabolites.
Compounds Percent nematode survival Mode of action Reference(s)
Epipolythiopiperazinedione (A22) 80% Binding to free protein thiols and generation of ROS [5]
Acetylgliotoxin (A3) 73% Binding to free protein thiols and generation of ROS [5]
Tunicamycin V (A15) 60% Inhibits the transfer of N-acetylglucosamine to a lipid intermediate [18,20]
Napthoquinone (A23) 53% Complex naphthoquinine; diverse biological properties
Enniatin A (A5) 47% Disrupt cellular physiological cation concentrations [22,47]
Desferrioxamine X (A10) 40% Hydroxamate siderophore – specific chelators of iron(III) [23,24]
Ascochlorin/Ilicicolin D (A1) 40% Inhibitor of the cytochrome bc1 complex in mitochondria [27,28]
Ilicicolin H (A4) 33% Inhibitor of the cytochrome bc1 complex in mitochondria [29,48]
(S)-Ochromycinone (A13) 33% Multiple biological properties, but exact MOA is unknown [49]
Tricothecin (A14) 33% Inhibits translation by binding to ribosomes [50,51]
Oligomycin A (A9) 27% Inhibitor of F0 domain of the H
+-ATP synthase [52]
Enniatin B1 (A12) 20% Disrupt cellular physiological cation concentrations [22,47]
doi:10.1371/journal.pone.0025321.t001
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responsible for the zone of inhibition observed with C. albicans and C.
neoformans. The area of the zone of inhibition produced by pure
gliotoxin was in a dose dependent manner as observed with AFS
(Figure 3). Pure gliotoxin produced a clear zone of inhibition of C.
albicans on Spider medium grown at 37uC as observed previously with
AFS, but the small zone of inhibition was not apparent with C. albicans
on YPD media grown at 30uC suggesting gliotoxin may not be
responsible for the slight observed inhibition in this condition (data not
shown). These studies demonstrate that gliotoxin is the major
component involved in the inhibitory activity of the A. fumigatus
supernatant when grown in Spider medium at 37uC.
The effects of gliotoxin in C. albicans and C. neoformans
Pure gliotoxin and AFS were used to find the minimum
inhibitory concentration (MIC) in vitro of C. albicans strains
DAY185, 95–120, 98–145, and C. neoformans strain KN99a. The
MIC of gliotoxin was 2.0 mg/ml for C. albicans and 4.0 mg/ml for
C. neoformans (Table 2), whereas the MIC of AFS was 3.2 mg/ml
for all the strains tested (Table 2). In murine studies, gliotoxin was
able to be accumulated in lung tissue to a mean concentration of
,4 mg/g and was also detected in the sera of the animals,
although at a significantly reduced concentration, 36 ng/mL [30].
Gliotoxin was capable of being detected in several patient serum
samples where the concentration of one sample was 785 ng/mL
(range 166–785 ng/mL) [30], suggesting gliotoxin can accumulate
in patients with invasive aspergillosis at a concentration capable of
inhibiting other fungal pathogens.
Gliotoxin is produced by a number of fungi [5], although
whether gliotoxin is produced by C. albicans is not known, as
conflicting studies exist suggesting gliotoxin is produced by some
strains of C. albicans [31], however subsequent studies have shown
that the fungus does not produce the ETP [32]. In support of the
lack of gliotoxin production in C. albicans, the genome of the fungus
does not contain a secondary metabolite gene cluster predicted to
synthesize an ETP [5], and this study demonstrates that C. albicans
is highly susceptible to gliotoxin (Figure 3; Table 2).
The toxicity of gliotoxin is possibly due to several mechanisms.
Gliotoxin has the potential to induce production of reactive
oxygen species (ROS) by a intracellular redox cycle, where the
reduced compound oxidizes to reform the disulfide bridge,
producing hydrogen peroxide and superoxide in the process [5].
Figure 3. Inhibition of C. albicans by A.f. supernatents and gliotoxin. C. albicans strains DAY185 (A) and 95–120 (B) grown on Spider medium
at 37uC overnight in the presence of discs containing the indicated amounts of AF293 supernatent (A.f. sup); supernatant from the DgliP mutant
unable to synthesize gliotoxin (gliP sup); or pure gliotoxin. The growth of C. albicans strain 98–145 in the presence of the treatments was similar to
95–120 (data not shown). C. C. neoformans wild type strain KN99a grown on YPD at 30uC overnight in the presence of discs containing indicated
amounts of A.f. sup or gliotoxin.
doi:10.1371/journal.pone.0025321.g003
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cellular proteins which have exposed cystine residues, and
therefore have no ‘‘specific’’ mode of action [5]. In addition, it
has been demonstrated that in mammalian cells the reduced form
of gliotoxin is unable to cross the plasma membrane, resulting in
accumulation inside the cell, and therefore the intracellular
concentration of gliotoxin is several orders of magnitude higher
and predominantly in the reduced form [33]. The hydrogen
peroxide produced by the redox cycle of gliotoxin has been
implicated in causing single- and double-stranded DNA breaks
[34], and therefore some of the antifungal activity of gliotoxin may
potentially also be derived by the damage of fungal DNA.
The effects of AFS and gliotoxin on C. albicans DAY185 were
further evaluated using the BacLight live-dead staining kit
(Molecular probes). Using this system, live fungi with intact
membranes fluoresce green, while dead fungi with damaged
membranes fluoresce red. The live-dead staining reflects the
previous observation where DMSO treated cells were alive (green),
and AFS (3.2 mg/ml) and gliotoxin (2.0 mg/ml) treated cells were
dead (red) in Spider medium at 37uC. At 30uC, C. albicans yeast
cells treated with DMSO and AFS (3.2 mg/ml) were alive (green,
Figure 3). In contrast, gliotoxin treated cells did not grow and the
nuclear contents were yellowish with the surrounding cytosol
green (Figure 4, gliotoxin treated cells in YPD at 30uC).
The inhibitory activity of gliotoxin (and AFS) treated C. albicans
cells was consistently higher against cells grown in Spider medium
compared to cells grown in YPD medium (Figures 3, 4 and S1).
Although the reason(s) for the observed differences are unknown,
we speculate that gliotoxin may have increased activity against
cells with a filamentous morphology which is favored by growing
C. albicans in Spider medium. Additionally, physiological proper-
ties such as permeability or increased ROS generation could
potentially be contributing to the antifungal activity of gliotoxin
when grown under this condition.
A. fumigatus is resistant to the effects of gliotoxin, as one of the
genes in the gli cluster, gliT, encodes a reductase that confers a high
level of self-protection to the compound [35]. Additionally,
another member of the gene cluster, gliA, encodes a major
facilitator transporter that has been shown to be involved in efflux
of the ETP [36]. Therefore, at least two mechanisms exist in A.
fumigatus that confer tolerance to gliotoxin that are absent in most
other fungi, including C. albicans and C. neoformans. In general there
are fewer efflux transporters in C. albicans and C. neoformans when
compared to A. fumigatus [37], and therefore are less likely to have
the capability to transport gliotoxin out of the cell. Of note is that
two fluconazole resistant isolates of C. albicans were as susceptible
to gliotoxin as the wild-type isolate suggesting the efflux pumps
conferring resistance to fluconazole do not confer resistance to
gliotoxin (Figure 3; Table 2). The lack of mechanisms able to
Table 2. MIC and EC50 of gliotoxin and A. fumigatus
supernatant as assessed in the C. elegans-C. albicans assay.*
MIC in vitro EC50
DAY185 95–120 98–145 KN99a DAY185
Gliotoxin (mg/ml) 2.0 2.0 2.0 4.0 2.0
A.fumigatus supernatant
(mg/ml)
3.2 3.2 3.2 3.2 1.0
*The MICs of gliotoxin were conduced in duplicate, while the MICs of the
A. fumigatus supernatant and the EC50 are based on a single measurement.
doi:10.1371/journal.pone.0025321.t002
Figure 4. Assessment of C. albicans viability after treatment with gliotoxin. Confocal laser microscopy of C. albicans after staining with the
Live/Dead staining system, whereby dead cells stain red and live cells stain green. C. albicans strain DAY185 was grown overnight in YPD at 30uCo ri n
Spider medium at 37uC, treated with DMSO, A. fumigatus supernatent (AFS; 3.2 mg/ml), or gliotoxin (2.0 mg/ml). The yellowish color is reflective of co-
localization of both red and green dyes suggesting the cells have increased permeability and maybe potentially dying or already dead. White arrows
showing intact nucleus with green color in DMSO and AFS treated cells, and partially dead nucleus with yellowish color in gliotoxin treated cells.
There was growth (++) in case of DMSO treated cells, partial growth (+) in A.f. sup treated cells, and no growth (-) in gliotoxin treated cells. Gliotoxin
treated cells were centrifuged before microscopy.
doi:10.1371/journal.pone.0025321.g004
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inhibitory activity of the compound.
C. elegans survival as a marker for the evaluation of the
antifungal activity of gliotoxin
The C. elegans-C. albicans model system was used to evaluate the
efficacy of AFS and gliotoxin using nematode survival as a method
to gauge the antifungal activity of the compound. Although other
invertebrate host models exist [38,39] C. elegans is an ideal
heterologous host to evaluate the effects of gliotoxin, as the
nematode lacks a NF-kB homolog while other immune response
pathways remain intact [40,41], and therefore some of the
immunosuppressive activity derived by inactivation of this
transcription factor does not interfere with the evaluation of the
antifungal activity of gliotoxin. AFS and gliotoxin were able to
inhibit the growth of C. albicans, prolonging the survival of C. elegans
(Figure 5). The effective concentration which resulted in 50%
survival of nematodes (EC50) of pure gliotoxin and AFS were
determined. The EC50 of AFS and gliotoxin were 1.0 mg/ml and
2.0 mg/ml, respectively (Table 2 and Figure 5). The highest
concentration of AFS used in the C. elegans assay was 12.8 mg/ml
(Table 2) a concentration that appeared to be non-toxic to the
nematode. As a control, the supernatant of C. neoformans was
unable to inhibit the growth of C. albicans and prolong the survival
of Candida-infected C. elegans (Figure 5).
Concluding remarks
Relatively few studies exist describing the interactions between
fungi, and usually these studies pertain to use of a fungus to control
a phytopathogenic fungus in agriculture. As the opportunistic
fungal pathogens C. albicans and A. fumigatus may exist within the
same infected individual or share a similar environmental niche,
it is imperative to understand the fungal-fungal interactions that
maybe taking place. Additionally, the inhibitory activity of
gliotoxin against pathogenic bacteria suggests this compound
may also have a role in the interaction between medically-
relevant bacteria and fungi capable of synthesizing the com-
pound, as these interactions may occur more frequently [42,43].
These interactions create a competition between these microbes
in order to obtain limited resources, and secondary metabolites
provide a competitive advantage to the microbe harboring them.
While gliotoxin production is related to virulence within a
susceptible host, this study indicates it may also facilitate A.
fumigatus colonization and maintenance within an individual by




C. albicans, C. neoformans, and A. fumigatus strains used in the
assays are listed in Table S1. Yeast strains were grown on yeast
extract-peptone-dextrose (YPD) (Difco) plates or in YPD liquid
media containing kanamycin (45 mg/ml), ampicillin (100 mg/ml),
and streptomycin (100 mg/ml) at 30uC. The inoculated liquid
media were grown over night on a rotary shaker at 225 rpm. The
cells were centrifuged, washed three times with phosphate buffered
saline (PBS) and re-suspended in PBS at the required concentra-
tions for experiments. The zone of inhibition assays were
conducted on either YPD plates at 30uC or on plates containing
Spider medium [44] at 37uC.
Figure 5. C. elegans-C. albicans co-infection assay to assess the ability of gliotoxin to promote nematode survival. Representative assay
wells from the C. elegans-C. albicans infection assay. The wells were treated with DMSO (negative control) or the indicated concentrations of A.f.
supernatant (A.f. sup), gliotoxin, or C. neoformans supernatant (C.n. sup). Sinusoidal shaped worms are alive (thick black arrows) and rod shaped
nematodes are dead (thin arrows).
doi:10.1371/journal.pone.0025321.g005
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A. fumigatus and C. neoformans culture supernatants were
obtained by growing single isolated colonies in glycerol-
arginine-yeast extract media [45] for 6–7 days at 30uC. The
liquid supernatant was then centrifuged, filter sterilized, and
lyophilized to obtain the crude concentrated fungal supernatants.
Dried fungal supernatants were then weighed and dissolved in an
appropriate amount of DMSO for use in subsequent assays.
Stock solutions of the supernatants were prepared at a
concentration of 200 mg/ml.
Minimal inhibitory concentration assay
The determination of the lowest concentration of the com-
pounds with antifungal activity was accomplished using two-fold
serial dilutions of the test compounds in RPMI 1640 media at
35uC for 24 hours [46]. The wells were assessed by a 96-well plate
reader (Vmax kinetic microplate reader, Molecular Devices,
Sunnyvale, CA) to determine the concentration exhibiting in vitro
inhibition of C. albicans growth.
Live-Dead staining
The viability of C. albicans in the presence of fungal supernatants
and gliotoxin was assessed by using the BacLight LIVE/DEAD
staining system according to the manufacturer’s protocol (Molec-
ular Probes, Carlsbad, CA). The cells which retained the green
fluorescence color were live whereas the red fluorescent cells were
considered dead.
EC50 assays
To measure the EC50 of gliotoxin and fungal supernatants on
worms, the C. albicans-C. elegans co-inoculation assay was performed
using the C. elegans glp-4;sek-1 double mutant in all assays [15].
Nematodes were maintained on nematode growth medium with
Escherichia coli strain OP50 as the food source. The screen medium
was 20% brain heart infusion medium (BHI, Difco) in M9 buffer
containing antibiotics kanamycin (90 mg/ml), ampicillin (200 mg/
ml), and streptomycin (200 mg/ml). M9 buffer was used to wash the
worms as needed and for the diluting the screen media.
At the end of the incubation period, the entire wells were
imaged, visually analyzed for in vitro fungal growth, followed by
visual scoring of live and dead worms based on worm shape, as live
worms appear sinusoidal and dead worms are rod shaped. The
worms were also tested by using a platinum pick to score live or
dead. For the determination of EC50, the test compounds were
serially diluted two-fold. Half the maximum effective concentra-
tion that conferred 50% survival of the worms was determined as
the EC50.
Supporting Information
Figure S1 Inhibition of C. albicans by heat inactivated
A.fumigatus supernatant. C. albicans strain DAY185 was
grown on YPD media at 30uC and Spider medium at 37uC
overnight in the presence of discs containing heat inactivated
supernatent from isolate AF293 (HI-AFS) at the indicated
concentrations.
(TIF)
Figure S2 Absence of inhibition of C. albicans growth by
C. neoformans supernatent. C. albicans strain DAY185 was
grown on YPD media at 30uC and Spider medium at 37uC
overnight in the presence of discs containing the supernatant of C.
neoformans strain KN99a (CNS) and the heat inactivated
supernatant of C. neoformans (HI-CNS) at the indicated concentra-
tions.
(TIF)
Table S1 Fungal isolates used in this study.
(DOC)
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